The use of genomic information is becoming a key piece of the oncology toolkit to make informed decisions aimed to improve the management of the disease and increase the cost-effectiveness of available therapies.
I am very happy to announce that our manuscript describing the increased mutation rate in Transcription Factor Binding Sites (TFBS) in melanomas and lung tumors has been published in today's issue of Nature. In the manuscript we demonstrate that this accumulation is due to the impairment of Nucleotide Excision Repair (NER) activity by proteins bound to DNA.
We are happy to announce that our lab has been awarded an European Research Council Consolidator Grant. ERC-consolidator grants are designed “To fund top researchers of any nationality and [...]
Coinciding with the publication of our latest paper, on Monday (9 March 2015) (See blog post) we have crafted a new IntOGen interface which presents the results of [...]
We are pleased to announce the publication of our paper in Cancer Cell describing the landscape of anti-cancer targeted therapeutic opportunities across a cohort of patients of [...]
Let’s plot some mutations! Easy, right? For our next iteration of the IntOGen database, we wanted to add figures that represent the mutation distribution across the protein [...]
We are pleased to announce that the Oncodrive methods family has a new member: OncodriveROLE, an approach to classify cancer drivers into loss of function and activating [...]
Cancers are typically classified depending on their tissue of origin. However, novel large-scale genomic studies are providing more detailed molecular characterizations of tumors, and thus bring about [...]
Recently, at least three articles have reviewed the ensemble of bioinformatics tools developed in the past few years to understand the alterations that plague the genome and [...]
Three years ago, Abel developed and published in the American Journal of Human Genetics an approach to combine the results of several tools aimed at identifying disease-related [...]